Immunotherapy with modified extract of Olea europaea pollen

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Rhinitis or Rhinoconjunctivitis With or Without Asthma Induced by Hypersensitivity to Olea Europea Pollen

Drug Information

Target Indication

Rhinitis or Rhinoconjunctivitis With or Without Asthma Induced by Hypersensitivity to Olea Europea Pollen

Clinical Trial

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

LRVIY

Laboratorios Farmaceuticos Rovi, S.A./ADR

Related Pipeline

Allergic Rhinoconjunctivitis

Osteoarthritis of Knee

Alopecia

Influenza, Human

Arterial Hypertension